The PECATI trial demonstrated promising activity of lenvatinib plus pembrolizumab in patients with pretreated metastatic B3 thymoma and thymic carcinoma, achieving a progression-free survival of 88.4% at 5 months. The safety profile was manageable, with notable severe adverse events including pneumonitis and hypertension but no treatment-related deaths.
Study
|
Single-arm, phase 2 trial [PECATI] |
| Adults with relapsed or recurrent metastatic type B3 thymoma or thymic carcinoma after platinum-based chemotherapy |
| Lenvatinib (20 mg daily) + Pembrolizumab (200 mg every 3 weeks) for a maximum of 35 cycles.
|
Efficacy
|
5-mo PFS: 88.4% [79.8-96.7] |
| mPFS: 14.9 mos [10.6-NE] |
| ORR: 23.3%
|
Safety
|
Grade >=3 AEs: Fatigue (2%), Diarrhoea (9%), Hypertension (7%), Abdominal pain (5%) |
| Serious AEs: Pneumonitis (5%) |
| No treatment-related deaths reported
|
Lancet Oncol. Published online 2025
Remon J, Bironzo P, Girard N New Indication: Lenvatinib + Pembrolizumab for Thymic Carcinoma
http://doi.org/10.1016/S1470-2045(25)00300-6
Reviewed by Ulas D. Bayraktar, MD on Oct 22, 2025
